Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020177 | 0.88 | LMNA (0.58) | MAPTKCNQ2LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL1099218 | 0.88 | LMNA (0.58) | MAPTKCNQ2LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL13389213 | 0.88 | LMNA (0.58) | MAPTKCNQ2LMNAHSD17B10SMN1; SMN2 | |
| Xenbucin SCHEMBL24134 | 0.87 | PTGS2 (0.58) | PTGS2MAPTKCNQ2LMNAHSD17B10 | |
| SCHEMBL4560385 | 0.84 | CTSS (0.50) | PTGS2MAPTKCNQ2LMNAHSD17B10 | |
| SCHEMBL16307712 | 0.84 | PTGS2 (0.50) | PTGS2MAPTLMNASMN1; SMN2L3MBTL1 | |
| Xenbucin SCHEMBL3360074 | 0.84 | PTGS2 (0.55) | PTGS2MAPTKCNQ2LMNAHSD17B10 | |
| SCHEMBL27620277 | 0.84 | PTGS2 (0.50) | PTGS2MAPTKCNQ2LMNAHSD17B10 | |
| Xenbucin SCHEMBL29388884 | 0.82 | PTGS2 (0.49) | PTGS2MAPTKCNQ2LMNAHSD17B10 | |
| SCHEMBL28434406 | 0.81 | GAA (0.52) | PTGS2MAPTKCNQ2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | PTGS2 1499/4885MAPT 1254/4885KCNQ2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.